

TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

AN OPEN ACCESS JOURNAL FOCUSING ON CLOSING THE GAP BETWEEN "BENCH AND BEDSIDE"

Annual Report 2021

Editorial Office

Email: editor@tlcr.org





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

Outline of the Report

1. Basic Information
2. Honorary Editors-in-Chief
3. Editors-in-Chief
4. Editorial Board Members
5. Publication: Number, Article Types, Internationality
6. Monthly Retrievals in PubMed (2015-2021)
7. Journal Impact Factor
8. Website Visits
9. Most Cited Articles in 2021
10. Special Series Published in 2021
11. Reviewers of the Month (2021)
12. Introduction of the Publisher AME




TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

1. Basic Information

- Open Access
- Peer Reviewed
- Launched in March 2012
- **Impact Factor: 6.498**
- Indexed by **Science Citation Index Expanded (SCIE), PubMed/PubMed Central, Scopus, Google Scholar, Medscape, Chemical Abstracts Service (CAS) Databases, MDlinx**
- Published quarterly (Mar. 2012 - Jan. 2013), bimonthly (Feb. 2013 - Dec. 2020), and monthly (Jan. 2021 -)
- The first international journal focusing on closing the gap between “Bench and Bedside” in lung cancer and related thoracic diseases.





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

1. Basic Information

TLCR is the official publication of:

- General Hospital of Eastern Theater Command, Nanjing, China
- Society for Translational Medicine (STM), Hong Kong

TLCR is endorsed by:

- Spanish Lung Cancer Group (SLCG)
- Bonnie J. Addario Lung Cancer Foundation (ALCF)
- Brazilian Society of Thoracic Surgery (SBCT)



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

2. Honorary Editors-in-Chief



Fred R. Hirsch, MD, PhD
Center for Thoracic Oncology,
Tisch Cancer Institute at Mount
Sinai, USA



Yi-Long Wu
Guangdong General Hospital
& Guangdong Academy of
Medical Sciences, China



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

3. Editors-in-Chief



Yong Song, MD, PhD
General Hospital of Eastern
Theater Command, China



Caicun Zhou, MD, PhD
Shanghai Pulmonary
Hospital, China




Rafael Rosell, MD, PhD
Dexeus University
Institute, Spain



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

4. Editorial Board Members



111 in totality, including:

- Two** Honorary Editors-in-Chief
- Three** Editors-in-Chief
- Four** Associate Editors-in-Chief
- One** Editor Emeritus
- Two** Associate Editor
- 99** Editorial Board Members

Updated on Dec 31, 2021






TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

5. Publication: Number



Till Dec 31, 2021, totally **1664** articles were published in TLCR.

The number of publication was increased from 2012-2014, yet it has kept a stability between 2014 and 2017, and has an obvious growth from 2018 to 2021 to meet the development of the journal as a monthly journal.

Updated on Dec 31, 2021






TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

5. Publication: Diverse Article Types



TLCR embraces diverse article types to meet demands from international authors and readers. The major article types published in TLCR include Original Article, Review Article and Editorial.

Updated on Dec 31, 2021






TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

5. Publication: Internationality



In total, **412** Corresponding Authors from **28** countries and regions contributed to TLCR in 2021, with the majority from **China, USA and Japan.**


Updated on Dec 31, 2021



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

6. Monthly Retrievals in PubMed (2015-2021)



This year, retrieval number of TLCR in PMC has reached up to a total of **784,842** times.

Source: PubMed Central Updated on Dec 31, 2021





TLCR


TRANSLATIONAL LUNG CANCER RESEARCH

7. Journal Impact Factor

2020 Journal Impact Factor & percentile rank in category for: Translational Lung Cancer Research

6.498

2020 Journal Impact Factor



Source: Web of Science Core Collection Updated on Dec 31, 2021






TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

8. Website Visits

Pageviews of TLCR Website in 2021



Country	Users	%Users
1. United States	85,155	34.16%
2. China	38,234	15.34%
3. India	23,537	9.44%
4. United Kingdom	13,521	5.42%
5. Japan	8,697	3.49%
6. Canada	6,148	2.47%
7. Australia	5,769	2.31%
8. South Korea	5,252	2.11%

According to the data collected from Google Analytics, there are altogether **246,482** users and **683,028** pageviews in 2021. Readers who visited TLCR website form diverse countries, with the majority from United States, followed by China, India, United Kingdom and Japan.

Source: Google Analytics Jan 1, 2021 - Dec 31, 2021





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

9. Most Cited Articles in 2021

Corresponding Author	Article Title
Shaker A. Mousa	Non-small cell lung cancer: current treatment and future advances
Brett G.M. Hughes	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Farhad Islami	Global trends of lung cancer mortality and smoking prevalence
Jeryl Villadolid	Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Alberto Ruano-Ravina	The epidemiology of lung cancer
Ming-Sound Tsao	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review
Hidetaka Uramoto	Recurrence after surgery in patients with NSCLC
Takashi Kohno	Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Jyoti Malhotra	Current state of immunotherapy for non-small cell lung cancer
Po Yee Yip	Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Source: Web of Science Core Collection Updated on Dec 31, 2021





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Special Series Published in 2021

- “New Era of Treatment for Unresectable Locally Advanced Non-Small Cell Lung Cancer” edited by



Zhengfei Zhu, MD
Fudan University Shanghai
Cancer Center, China



Xiaolong Fu
Shanghai Chest Hospital,
China



Steven H. Lin, MD, PhD
The University of Texas MD
Anderson Cancer Center, USA



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Special Series Published in 2021

➤ “Oligometastatic NSCLC: Definition and Treatment Opportunities” edited by



Maurizio V. Infante, MD
University and Hospital Trust, Verona,
Italy



Thierry Berghmans, MD, PhD
Institute Jules Bordet, Université Libre
de Bruxelles, Brussels, Belgium




TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Special Series Published in 2021

- **“Immunotherapy in Other Thoracic Malignancies and Uncommon Populations”**
edited by



Jordi Remon, MD
Hospital HM Delfos, HM
Hospitales, Barcelona, Spain



Benjamin Besse, MD, PhD
Université Paris-Saclay, Villejuif,
France



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Special Series Published in 2021

➤ “Lung Cancer and The Immune System” edited by



Daniel Steinfors, MBBS, BMedSci, FRACP, PhD
University of Melbourne,
Melbourne, Australia



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Special Series Published in 2021

➤ “Lung cancer screening” edited by



Paul Van Schil, MD, PhD
Antwerp University Hospital,
Antwerp, Belgium



Annemiek Snoeckx, MD, PhD
Antwerp University Hospital,
Antwerp, Belgium



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Special Series Published in 2021

➤ “Radiotherapy in thoracic malignancies” edited by



Jacek Jassem, MD, PhD
Medical University of Gdańsk,
Gdańsk, Poland.



Rafal Dziadziuszko, MD, PhD
Medical University of Gdańsk,
Gdańsk, Poland.



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Special Series Published in 2021

➤ “Implementation of CT-based screening of lung cancer” edited by



Witold Rzyman, MD, PhD
Medical University of Gdansk,
Gdańsk, Poland



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

10. Special Series Published in 2021

- **“Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer”**
edited by



Mariano Provencio, MD, PhD
Hospital Universitario Puerta de Hierro,
Madrid, Spain



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH


10. Special Series Published in 2021

- “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” edited by



Silvia Novello, MD, PhD

University of Turin, San Luigi Hospital,
Orbassano, Italy



Francesco Passiglia, MD, PhD

University of Turin, San Luigi Hospital,
Orbassano, Italy



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

11. Reviewers of the Month (2021)

In 2021, many TLCR reviewers have made outstanding contributions to the peer review process. Hereby, we would like to highlight a few of them as follows in form of interview. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

January, 2021

Sung Yong Lee, University Guro Hospital, Korea

Michael Pritchett, FirstHealth of the Carolinas & Pinehurst Medical Clinic, USA

February, 2021

Mizuho Nishio, Kobe University Hospital, Japan

Ernest Nadal, Catalan Institute of Oncology, Spain

March, 2021

Petros Christopoulos, Heidelberg University Hospital, Germany

Kang-Yi Su, National Taiwan University, Taiwan

Menno Tamminga, University of Groningen, the Netherlands

April, 2021

Kyoji Hirai, Nippon Medical School Chiba Hokusoh Hospital, Japan

Artur Mezheyeuski, Uppsala University, Sweden

Alexander Gill, Johns Hopkins University, USA

Muhammad Zubair Afzal, Norris Cotton Cancer Centre, USA





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

11. Reviewers of the Month (2021)

In 2021, many TLCR reviewers have made outstanding contributions to the peer review process. Hereby, we would like to highlight a few of them as follows in form of interview. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

May, 2021

Masahide Oki, National Hospital Organization Nagoya Medical Center, Japan

Yasushi Shintani, Respiratory Center in the Osaka University Hospital, Japan

Taichiro Goto, Yamanashi Central Hospital, Japan

Pierre-Jean Lamy, Imagenome Montpellier, France

June, 2021

Rafael Rosell, Germans Trias i Pujol Research Institute and Hospital, Spain

Taiki Hakozaiki, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

July, 2021

Florian Eichhorn, Thoraxklinik Heidelberg University Hospital, Germany

August, 2021

Wolfgang M. Brueckl, University of Erlangen-Nuremberg, Germany

Kadoaki Ohashi, Okayama University Hospital, Japan

Ukhyun Jo, National Cancer Institute, National Institutes of Health, USA

Martin P. Barr, Trinity St James's Cancer Institute, Ireland



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

11. Reviewers of the Month (2021)

In 2021, many TLCR reviewers have made outstanding contributions to the peer review process. Hereby, we would like to highlight a few of them as follows in form of interview. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

September, 2021

Rui Haddad, Pontifical Catholic University of Rio de Janeiro, Brazil

Per Hydbring, the Karolinska Institutet, Sweden

Ajay Wagh, University of Chicago, USA

October, 2021

Akira Ono, Shizuoka Cancer Center, Japan

Yeul Hong Kim, Korea University, Korea

November, 2021

Umberto Malapelle, University Federico II of Naples, Italy

Hae-Seong Nam, Inha University Hospital, Korea

Lukas Käsmann, Ludwig Maximilian University, Germany

Yuji Matsumoto, National Cancer Center Hospital, Japan

Dwight Owen, The Ohio State University, USA



TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

12. Introduction of the Publisher AME

Meet our Publisher:

AME Publishing Company

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world

- 60+ peer-reviewed journals
 - 13 indexed in SCIE
 - 20 indexed in PubMed/PMC/MEDLINE

- 200+ Medical Books
 - 80+ Medical Books in English
 - 120+ Medical Books in Chinese
- 150+ Electronic Editions





TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

Thank You for All Your Support!

